


3

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Applicants: Erik H.F. Wong et al.
 Serial No.: To be assigned
 Filed: September 24, 2003
 (Herewith)
 Title: METHOD OF TREATING
 FIBROMYALGIA AND OTHER
 SOMATOFORM DISORDERS
 Group Art Unit: To be assigned
 Examiner: To be assigned
 Attorney Docket No.: 28341/6248.10

) I hereby certify that this paper is being
) deposited with the United States Postal
) Service, on **September 24, 2003**, in an
) envelope addressed to Mail Stop Patent
) Application, Commissioner for Patents,
) P.O. Box 1450, Alexandria, Virginia
) 22313-1450, utilizing the "Expresss Mail
) Post Office to Addressee" service of the
) United States Postal Service under
) Mailing Label No. **EV 323772465 US**.


 Richard Zimmermann

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97(b), enclosed herewith is a completed Form PTO-1449 identifying documents that may be considered material to the examination of the above-identified application.

The above-identified application is a division of, and claims priority benefit under 35 U.S.C. § 120 to, pending U.S. Serial No. 10/255,450 (filed September 26, 2002), which itself is a division of, and claims priority benefit under § 120 to, U.S. Serial No. 09/599,213 (filed June 22, 2000) now U.S. Patent No. 6,465,458.

U.S. Patent No. 6,610,690 issued on August 26, 2003, from U.S. Serial No. 10/037,344, which is a division of, and claims priority benefit under § 120 to, the '213 application.

Enclosed herewith and identified on the enclosed Form PTO-1449 are copies of the following:

- (a) U.S. Patent No. 6,465,458;
- (b) U.S. Patent No. 6,610,690; and,
- (c) Notice of Allowance and Fee(s) Due in U.S. Serial No. 10/037,344.

Pursuant to 37 C.F.R. § 1.98(d), copies of the other documents identified on the accompanying Form PTO-1449 are not being enclosed as each was previously submitted during prosecution of the '213 application. However, the applicants will be pleased to provide additional copies should the examiner so desire.


An early and favorable action on the merits is respectfully requested.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

September 24, 2003

By:



Sandip H. Patel (Reg. No. 43,848)
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300 TELEPHONE

Form PTO-1449 (Modified)

Atty. Docket No.
28341/6248.10

Serial No.

INFORMATION DISCLOSURE STATEMENTApplicant(s)
Erik H.F. Wong et al.Filing Date
September 24, 2003

Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)
	4,229,449	10-21-1980	Melloni et al.			
	4,596,807	06-24-1986	Crosby			
	5,068,433	11-26-1991	Melloni et al.			
	5,192,751	03-09-1993	Thor			
	5,281,624	01-25-1994	Gehlert et al.			
	5,391,735	02-21-1995	Melloni et al.			
	5,441,985	08-15-1995	Foreman			
	5,744,474	04-28-1998	Thor			
	5,922,914	07-13-1999	Gage et al.			
	5,998,430	12-07-1999	Schwantes et al.			
	6,028,070	02-22-2000	Heiligenstein			
	6,046,193	04-04-2000	Heiligenstein			
	6,066,643	05-23-2000	Perry			
	6,465,458	10-15-2002	Wong et al.			
	6,610,690	08-26-2003	Wong et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation	
				Yes	No
	2,014,981	09-05-1979	United Kingdom		
	2,167,407	05-11-1988	United Kingdom		
	WO 96.12485	05-02-1996	PCT		
	WO 97/35584	10-02-1997	PCT		

EXAMINER:

DATE CONSIDERED:

Form PTO-1449 (Modified) INFORMATION DISCLOSURE STATEMENT	Atty. Docket No. 28341/6248.10	Serial No.
	Applicant(s) Erik H.F. Wong et al.	
	Filing Date September 24, 2003	Art Unit

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Document Number	Publication Date	Country	Translation	
				Yes	No
	WO 97/35586	10-02-1997	PCT		
	WO 99/15163	04-01-1999	PCT		
	WO 99/15176	04-01-1999	PCT		
	WO 99/15177	04-01-1999	PCT		
	WO 99/20279	04-29-1999	PCT		
	WO 99/52531	10-21-1999	PCT		
	WO 99/52518	10-21-1999	PCT		
	WO 99/58130	11-18-1999	PCT		

OTHER DOCUMENTS	
	J.J. Schildkraut, The Catecholamine Hypothesis of Affective Disorders: A Review of Supporting Evidence. <i>Am. J. Psychiatry</i> , Vol. 122, pp. 509-22 (Nov. 1965).
	T.H. Svensson, et al., Feedback Inhibition of Brain Noradrenaline Neurons by Tricyclic Antidepressants: α -Receptor Mediation, <i>Science</i> , Vol. 202, pp. 1089-91 (1984).
	E. Richelson et al., Blockade by Antidepressants and Related Compounds of Biogenic Amine Uptake into Rat Brain Synaptosomes: Most Antidepressants Selectively Block
	C.B. Nemeroff, The Neurobiology of Depression, <i>Scientific American</i> (1988) (8 pages).
	M. Riva et al., Effect of Reboxetine, A New Antidepressant Drug, on the Central Noradrenergic System: Behavioral and Biochemical Studies, <i>J. Drug Dev.</i> , Vol. 1, no. 4,
	T. Pacholczyk et al., Expression Cloning of a Cocaine-and Antidepressant-Sensitive Human Noradrenaline Transporter, <i>Nature</i> , Vol. 350, no. 28, pp. 350-56 (March 1991).
	M. Max et al., Efficacy of Desipramine in Painful Diabetic Neuropathy: A Placebo-Controlled Trial, <i>Pain</i> , Vol. 45, pp. 3-9 (1991).
	E. Richelson, Biological Basis of Depression and Therapeutic Relevance, <i>J. Clin. Psychiatry</i> , Vol. 52, no. 6 Suppl., pp. 4-10 (June 1991).
	M. Max et al., Effects of Desipramine Amitriptyline and Fluoxetine on Pain in Diabetic Neuropathy, <i>New Engl. J. Med.</i> , Vol. 326, No. 19, pp. 1250-56 (1992).
	B. Cusack et al., Binding Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds, <i>Psychopharmacology</i> , Vol. 114, pp. 559-65 (1994).
	M. Max, "Treatment of Post-Herpetic Neuralgia: Antidepressants," <i>Ann. Neurol.</i> , Vol. 35, Suppl., pp. s50-s53 (1994).

EXAMINER:	DATE CONSIDERED:
-----------	------------------

Form PTO-1449 (Modified)	Atty. Docket No. 28341/6248.10	Serial No.
	Applicant(s) Erik H.F. Wong et al.	
	Filing Date September 24, 2003	Art Unit

INFORMATION DISCLOSURE STATEMENT

	W. Reimann et al., "Inhibition of Spinal Noradrenaline Uptake in Rats by the Centrally Acting Analgesic Tramadol," <u>Biochem. Pharmacol.</u> , Vol. 47, No. 12, pp. 2289-93 (1994).
	C. Pellizzoni et al., Pharmacokinetics of Reboxetine in Healthy Volunteers, Single Against Repeated Oral Doses and lack of Enzymatic Alterations, <u>Biopharm. Drug Dispos.</u> , Vol. 19, No. 3, pp. 251-256 (1998).
	R.J. Baldessarini, Depression and Mania, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Chapter 19, pp. 431-39, (1996).
	B.E. Leonard, Noradrenaline in Basic Models of Depression, <u>European Neuropsychopharmacology</u> , Vol. 7, Suppl. 1, pp. S11-S16 (1997).
	Discussion, <u>European Neuropsychopharmacology</u> , Vol. 7, Suppl. 1, pp. S71-S73 (1997).
	S.A. Montgomery, Is There a Role for a Pure Noradrenergic Drug in the Treatment of Depression?, <u>Eur. Neuropsychopharmacology</u> , Vol. 7, Suppl. 1, pp. S3-S9 (1997).
	S.A. Montgomery, Reboxetine: Additional Benefits to the Depressed Patient, <u>J. Psychopharmacology (Oxf)</u> , 11:4 Abstract (1997).
	I. Hindmarch, The Effects of Antidepressants on Psychomotor Function with Particular Reference to Reboxetine, <u>Eur. Neuropsychopharmacology</u> , Vol. 7, Suppl. 1, pp. S17-S21 (1997).
	E. Frigerio et al., Pharmacokinetics of Reboxetine Enantiomers in the Dog, <u>Chirality</u> , Vol. 9, pp. 303-06 (1997).
	A. Frazer, Pharmacology of Antidepressants, <u>J. Clinical Psychopharmacology</u> , Vol. 17, no. 2, Suppl. 1, pp. 2S-18S (1997).
	B.E. Leonard, The Role of Noradrenaline in Depression: A Review, <u>J. Psychopharmacology</u> , Vol. II, No. 4, Suppl. pp. S39-S47 (1997).
	Dostert et al., Review of the Pharmacokinetics and Metabolism of Reboxetine, A Selective Noradrenaline Reuptake Inhibitor, <u>Euro. Neuropsychopharmacol.</u> , Vol. 7, Suppl. 1, pp. S1-S4 (1997).
	M. Owens et al., "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites," <u>J. Pharmacol. Exp. Ther.</u> , Vol. 283, pp. 1305-1312 (1998).
	D. Healy et al., The Clinical Pharmacologic Profile of Reboxetine: Does it Involve the Putative Neurobiological Substrate of Wellbeing?, <u>J. of Affective Disorders</u> , Vol. 1, pp. 1-10 (1998).
	Anonymous, Reboxetine - Another New Antidepressant, <u>Drugs and Therapeutics Bull.</u> , 36 (11) (1998).
	S.A. Montgomery, The Place of Reboxetine in Antidepressant Therapy, <u>J. of Clinical Psychiatry</u> , Vol. 59, Suppl. 14, pp. 26-29 (1998).
	G.D. Burrows et al., Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review, <u>J. Clin. Psychiatry</u> , Vol. 59, Suppl. 14, 4 pages (1998).
	J. Massana, Reboxetine Versus Fluoxetine: An Overview of Efficacy and Tolerability, <u>J. Clin. Psychiatry</u> , Vol. 59, Suppl. 14, pp. 8-10 (1998).
	A. Harkin et al., Activity and Onset of Action of Reboxetine and Effect of Combination with Sertraline in an Animal Model of Depression, <u>Eur. J. of Pharmacology</u> , pp. 1-10 (1998).
	J. Massana et al., Reboxetine: A Double-Blind Comparison with Fluoxetine in Major Depressive Disorder, <u>Int. Clin. Psychopharmacol.</u> , Vol. 14, No. 2, pp. 73-80 (1999).
	J.C. Fleishaker et al., Absolute Bioavailability of Reboxetine Enantiomers and Effect of Gender on Pharmacokinetics, <u>Biopharm. Drug Dispos.</u> , Vol. 20, No. 1, pp. 53-57 (1999).
	K. Moore et al., "Tissue Distribution of Tramadol and Metabolites in an Overdose Fatality," <u>Am. J. of Forensic Med. and Path.</u> , Vol. 20, No. 1, pp. 98-100 (1999).
	S. Kasper, From Symptoms to Social Functioning: Differential Effects of Antidepressant Therapy, <u>International Clinical Psychopharmacology</u> , Vol. 14, Suppl. 1, pp. S27-S31 (1999).

EXAMINER:

DATE CONSIDERED:

Form PTO-1449 (Modified) INFORMATION DISCLOSURE STATEMENT	Atty. Docket No. 28341/6248.10	Serial No.
	Applicant(s) Erik H.F. Wong et al.	
	Filing Date September 24, 2003	Art Unit

	International Search Report in PCT/US00/17256 dated July 12, 2001.
	International Preliminary Examination Report in PCT/US00/17256 dated December 19, 2001.
	"Notice of Allowance and Fee(s) Due" dated March 25, 2003, sent by the United States Patent and Trademark Office for U.S. Serial No. 10/037,344 (4 pages).

EXAMINER:	DATE CONSIDERED:
-----------	------------------